Dalbavancin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dalbavancin: From Gram-Positive Bacterial Infections to Postinfectious Vasculitis
One-Sentence Summary
Dalbavancin is a long-acting intravenous lipoglycopeptide antibiotic used against Gram-positive bacterial infections. The TxGNN model predicts it may be effective for postinfectious vasculitis, but this rests on the model score alone, with 0 clinical trials and 0 publications supporting this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-positive bacterial infections (the approved indication text was not provided; this is inferred from the drug class and the registered trials) |
| Predicted New Indication | Postinfectious vasculitis |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 4 authorizations (1 NDA and 3 generic ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the source record. Dalbavancin belongs to the lipoglycopeptide class, and its known activity is against Gram-positive bacteria. It is used against active infections such as skin and soft tissue infection.
The link to the predicted indication is weak. Postinfectious vasculitis is usually immune-complex mediated, so it is driven by the immune response after an infection rather than by persistent bacteria. No antibacterial mechanism clearly applies, and the high graph score may reflect a knowledge-graph association rather than real biology.
Clinical Trial Evidence
Currently no related clinical trials registered for postinfectious vasculitis.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA021883 | DALVANCE | Injection, powder, for solution | Allergan, Inc. |
| ANDA217591 | Dalbavancin Hydrochloride | Injection, powder, for solution | Fresenius Kabi USA, LLC |
| ANDA219465 | Dalbavancin | Injection, powder, for solution | Teva Pharmaceuticals, Inc. |
| ANDA218929 | Dalbavancin | Injection, powder, lyophilized, for solution | Meitheal Pharmaceuticals Inc |
All products are injectables. The approved indication text was not included in the source record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5), and the disease is immune-mediated, so an antibacterial mechanism is not evident. The approval history supports use in active Gram-positive infections only.
Other predictions in the list (not part of this decision):
- Post-bacterial disorder (rank 2) has 13 dalbavancin trials, including several Phase 3 RCTs. These test active Gram-positive infection, not post-infectious sequelae, so the link is indirect.
- Orbital cellulitis (rank 10) is the most mechanistically plausible of the ten, because S. aureus and streptococci are within dalbavancin’s spectrum. It is flagged as a research question, but it has no orbital-specific evidence and tissue penetration is unknown.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence that dalbavancin affects immune-mediated vasculitis
- A decision on whether to reprioritize toward an infection-based candidate, such as orbital cellulitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.